Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification Presented new nonclinical data showing ALRN-6924 reduced chemotherapy-related toxicities (“myelopreservation”) in cellular studies and mouse models of cancer without…
Read MoreNonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Aileron…
Read MoreNonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE)…
Read More